Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

Jemperli, a cancer drug manufactured by GlaxoSmithKline, improved survival for patients diagnosed with a form of uterine cancer by more than one year, the British drugmaker said Saturday ...

Finally, the assay can be used with Merck’s Keytruda (pembrolizumab) and GSK’s Jemperli (dostarlimab) across solid tumors ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

Jemperli – the seventh approved drug in the PD-1/PD-L1 inhibitor class – was acquired by GSK as part of its $5.1 billion takeover of Tesaro along with PARP inhibitor Zejula (niraparib ...

The European Commission (EC) has granted marketing authorisation for GSK’s Jemperli (dostarlimab) plus chemotherapy regimen to treat adults with primary advanced or recurrent endometrial cancer.

GSK says its PD-1 inhibitor Jemperli compared favourably with Merck & Co’s Keytruda in a head-to-head trial in previously-untreated non-small cell lung cancer (NSCLC), with numerically higher ...

Mark A. Lewis, MD, discusses dostarlimab-gxly and how experts can best counsel patients with locally advanced mismatch repair ...

A curated review of what has happened in endometrial cancer research in 2024, including expert commentary, FDA approvals, healthcare disparities, AI, immunotherapies, and more.

Earlier this year, the FDA approved GSK's Jemperli in combination with chemotherapy, followed by Jemperli as a single agent in treating primary advanced or recurrent endometrial cancer.

In oncology, we were delighted that Jemperli received an expanded approval by the FDA for all adult patients with primary advanced or recurrent endometrial cancer. And Blenrep is now filed with ...

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...